Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 4
2011 4
2012 2
2013 2
2014 2
2015 2
2016 3
2017 7
2018 8
2019 8
2020 16
2021 16
2022 15
2023 14
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: di pauli f. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. Tur C, et al. Among authors: di pauli f. Mult Scler. 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23. Mult Scler. 2022. PMID: 35196927 Review.
Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum.
Berek K, Bauer A, Rudzki D, Auer M, Barket R, Zinganell A, Lerch M, Hofer L, Grams A, Poskaite P, Wurth S, Berger T, Di Pauli F, Deisenhammer F, Hegen H, Reindl M. Berek K, et al. Among authors: di pauli f. Front Immunol. 2023 Jun 13;14:1200146. doi: 10.3389/fimmu.2023.1200146. eCollection 2023. Front Immunol. 2023. PMID: 37383229 Free PMC article.
Screening for osteoporosis in people with MS: A new risk score.
Zinganell A, Hegen H, Walde J, Bauer A, Berek K, Barket R, Auer M, Bsteh G, Donnemiller E, Egger A, Grams A, Griesmacher A, Kroiss AS, Rettenwander F, Tschallener M, Tschoner A, Berger T, Deisenhammer F, Di Pauli F. Zinganell A, et al. Among authors: di pauli f. Mult Scler Relat Disord. 2023 Jun;74:104726. doi: 10.1016/j.msard.2023.104726. Epub 2023 Apr 17. Mult Scler Relat Disord. 2023. PMID: 37098303 Free article.
Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders.
Habek M, Andabaka M, Fanciulli A, Brecl Jakob G, Drulović J, Leys F, Di Pauli F, Hegen H, Auer M, Pekmezović T, Mesaroš Š, Jovičević V, Junaković A, Wenning GK, Deisenhammer F, Gabelić T, Barun B, Adamec I, Krbot Skorić M. Habek M, et al. Among authors: di pauli f. Eur J Neurol. 2022 Sep;29(9):2772-2780. doi: 10.1111/ene.15413. Epub 2022 Jun 12. Eur J Neurol. 2022. PMID: 35598288
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
Monschein T, Dekany S, Zrzavy T, Ponleitner M, Altmann P, Bsteh G, Kornek B, Rommer P, Enzinger C, Di Pauli F, Kraus J, Berger T, Leutmezer F, Guger M; Austrian MS Treatment Registry (AMSTR). Monschein T, et al. Among authors: di pauli f. J Neurol. 2023 Aug;270(8):3779-3786. doi: 10.1007/s00415-023-11686-2. Epub 2023 Apr 19. J Neurol. 2023. PMID: 37074388 Free PMC article.
Multiple sclerosis and COVID-19: How many are at risk?
Bsteh G, Bitschnau C, Hegen H, Auer M, Di Pauli F, Rommer P, Deisenhammer F, Berger T. Bsteh G, et al. Among authors: di pauli f. Eur J Neurol. 2021 Oct;28(10):3369-3374. doi: 10.1111/ene.14555. Epub 2020 Oct 22. Eur J Neurol. 2021. PMID: 32978860 Free PMC article.
95 results